NEW YORK, July 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT).Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/rocket-pharmaceuticals-inc-loss-submission-form/?id=156038&from=4CLASS PERIO ...

Core Viewpoint - Oncolytics Biotech Inc. is hosting a KOL webinar on July 22, 2025, to discuss the immunotherapeutic agent pelareorep in the context of metastatic pancreatic ductal adenocarcinoma and other gastrointestinal cancers [1][2]. Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer [10][11]. - Pelareorep works by inducing anti-cancer immune responses and transforming "cold" tumors into "hot" tumors, enhancing the effectiveness of various cancer treatments [10]. Webinar Details - The webinar will feature key opinion leaders (KOLs) including Dirk Arnold, Alexander Eggermont, Sanjay Goel, and Devalingam Mahalingam, who will discuss existing clinical data and the potential of pelareorep in treating mPDAC and other gastrointestinal cancers [2][4][5][6][8]. - A live Q&A session will follow the formal presentation and roundtable discussion [3]. KOL Profiles - Dirk Arnold, M.D., Ph.D., is a prominent figure in gastrointestinal cancers and immunotherapy, with extensive experience in clinical trials [4]. - Alexander Eggermont, M.D., Ph.D., has a strong background in clinical and translational immunotherapy, having authored over 900 peer-reviewed papers [5]. - Sanjay Goel, M.D., M.S., FASCO, focuses on drug development and health disparities, with over 150 research publications [6][7]. - Devalingam Mahalingam, M.D., Ph.D., specializes in early-phase clinical studies and has been involved in numerous clinical trials [8][9].

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Breaking Through: Systemic Genetic Medicines f ...

In a market increasingly defined by volatility and uncertainty, investors are grappling with a mix of opportunities and risks. The recent turmoil in the tech sector, particularly among companies heavily reliant on artificial intelligence, has raised questions about sustainability and profitability.On CNBC's “Mad Money Lightning Round,” Jim Cramer said Tempus AI, Inc. TEM is another company that's just losing money “hand over fist,” so he recommended not going there.According to recent news, Personalis, Inc. ...

Core Viewpoint - Kaskela Law LLC is investigating Solid Biosciences Inc. due to a significant decline in its stock price, which has dropped over 40% since September 2024 [1][2]. Group 1: Stock Performance - Solid Biosciences' stock price has decreased from over $10.00 per share to less than $6.00 per share, representing a decline of over 40% [1]. Group 2: Legal Investigation - The investigation aims to determine if Solid Biosciences and its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions [2].

Core Insights - PDS Biotechnology Corporation has completed patient recruitment for Stage 1 of a clinical trial for its PDS01ADC therapeutic in combination with floxuridine for metastatic colorectal cancer, leading to an expansion into Stage 2 of the study [1][2] Group 1: Clinical Trial Details - The trial is an open-label, single-center, non-randomized Phase 2 study with three cohorts: metastatic colorectal cancer, cholangiocarcinoma, and adrenocortical cancer [2] - The colorectal cancer cohort achieved the milestone of at least 6 out of 9 participants showing an objective response, allowing enrollment to continue up to 22 participants [2] - The study is conducted under a collaborative research and development agreement with the National Cancer Institute (NCI) [2] Group 2: Product Information - PDS01ADC is a fused antibody drug conjugate that targets tumor necrosis by binding to exposed DNA [3] - The investigational approach aims to minimize systemic exposure to IL-12, potentially reducing treatment-limiting toxicities [4] Group 3: Market Context - Colorectal cancer is a significant health issue, with over 930,000 deaths globally in 2020, highlighting the need for more effective treatments [4] - In the U.S., over 150,000 new cases of colorectal cancer are diagnosed annually, with 20% already metastatic at diagnosis [4]

PALO ALTO, Calif.  , July 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics, announced today it will host an investor R&D Day webcast on Wednesday, July 16, 2025, from 4:00 pm ET to 5:30 pm ET.The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of ...

Core Viewpoint - Kaskela Law LLC is investigating Amicus Therapeutics, Inc. on behalf of its shareholders due to a significant decline in stock value and potential violations of securities laws or breaches of fiduciary duties by the company's officers and directors [1][2]. Group 1: Stock Performance - Year to date, shares of Amicus' stock have declined over 32% in value, trading at a current price of less than $7.00 per share [2]. Group 2: Legal Investigation - The investigation aims to determine if Amicus and/or its officers and directors violated securities laws or breached fiduciary duties in connection with recent corporate actions [2]. - Shareholders are encouraged to contact Kaskela Law LLC for additional information regarding the investigation and their legal rights [3].

Core Insights - e-therapeutics plc has made significant progress with its lead candidate ETX-312, a GalOmic siRNA therapy for metabolic dysfunction-associated steatohepatitis (MASH), and is on track to submit a clinical trial application (CTA) in Q4 2025 [1][4] Group 1: Clinical Development Progress - ETX-312 was well tolerated in GLP-compliant toxicology studies at doses far exceeding anticipated clinical exposure, indicating a broad therapeutic window [2][4] - The company has successfully completed GMP manufacturing of the clinical batch of ETX-312, demonstrating operational readiness for first-in-human dosing [3][4] - The tolerability profile of ETX-312 supports the clinical strategy and plans for a CTA filing in Q4 2025 [4] Group 2: Product Details - ETX-312 is a GalNAc-conjugated small-interfering RNA therapeutic candidate aimed at treating MASH, with potential for quarterly subcutaneous dosing [5] - Preclinical studies have shown that ETX-312 leads to significant reductions in NAFLD Activity Score (NAS), decreased hepatic inflammation, and slowed fibrosis progression [5] Group 3: Company Overview - e-therapeutics plc combines computational power and RNAi to develop innovative medicines, utilizing its proprietary GalOmic platform for effective gene silencing [6][7] - The company has established a robust position in applying computational approaches to biology, validated through successful collaborations with biopharma companies [6][7]

Core Viewpoint - IGI Therapeutics and AbbVie have entered into an exclusive licensing agreement for ISB 2001, a novel trispecific T-cell engager targeting multiple myeloma, which is currently in Phase 1 clinical trials [1][2]. Company Overview - IGI Therapeutics is a clinical-stage biotechnology company focused on developing innovative biologics in oncology, utilizing its proprietary BEAT® technology platform to create first-in-class multispecific therapies [7]. - AbbVie is a global biopharmaceutical company dedicated to discovering and delivering innovative medicines across various therapeutic areas, including oncology [8]. Product Details - ISB 2001 is designed to target BCMA and CD38 on myeloma cells and CD3 on T cells, aiming to improve safety and efficacy compared to first-generation bispecific antibodies [3]. - The drug has shown a sustained overall response rate (ORR) of 79% and a complete/stringent complete response (CR/sCR) rate of 30% in a heavily pretreated patient population [3]. Licensing Agreement - Under the agreement, AbbVie will have exclusive rights to develop, manufacture, and commercialize ISB 2001 in North America, Europe, Japan, and Greater China [2]. - IGI will receive an upfront payment of $700 million and could earn up to $1.225 billion in milestone payments, along with tiered, double-digit royalties on net sales [2]. Regulatory Designations - ISB 2001 received Orphan Drug Designation from the U.S. FDA in July 2023 and Fast Track Designation for treating relapsed/refractory myeloma patients in May 2025 [4]. BEAT® Platform - The BEAT® platform enables the development of next-generation immune cell engagers with enhanced stability and function, addressing limitations of traditional bispecific antibody production [5]. - Key features include multispecific versatility, optimized engineering for precise modulation, and robust manufacturability [5].